Inscription Capital LLC Sells 739 Shares of Novo Nordisk A/S (NYSE:NVO)

Inscription Capital LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 22.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,526 shares of the company’s stock after selling 739 shares during the quarter. Inscription Capital LLC’s holdings in Novo Nordisk A/S were worth $301,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Novo Nordisk A/S by 14.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after purchasing an additional 37,346 shares during the last quarter. Independence Bank of Kentucky increased its position in Novo Nordisk A/S by 192.7% in the 3rd quarter. Independence Bank of Kentucky now owns 11,490 shares of the company’s stock valued at $1,368,000 after acquiring an additional 7,565 shares in the last quarter. Cetera Investment Advisers raised its stake in shares of Novo Nordisk A/S by 453.3% in the first quarter. Cetera Investment Advisers now owns 265,538 shares of the company’s stock worth $34,095,000 after acquiring an additional 217,545 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of Novo Nordisk A/S during the second quarter valued at approximately $1,624,000. Finally, Azzad Asset Management Inc. ADV increased its holdings in shares of Novo Nordisk A/S by 55.9% in the third quarter. Azzad Asset Management Inc. ADV now owns 41,107 shares of the company’s stock valued at $4,895,000 after purchasing an additional 14,731 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of recent research reports. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 9th. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, October 10th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average price target of $144.50.

Novo Nordisk A/S Trading Down 0.9 %

NYSE:NVO opened at $112.39 on Tuesday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The firm has a market capitalization of $504.35 billion, a price-to-earnings ratio of 38.49, a PEG ratio of 1.48 and a beta of 0.42. The business’s 50-day moving average price is $126.16 and its two-hundred day moving average price is $131.28.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The firm had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. On average, equities analysts expect that Novo Nordisk A/S will post 3.01 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were issued a $0.5126 dividend. This represents a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 24.66%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.